3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
6
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Salivary Gland Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Magnetic Resonance Spectroscopy
24
Temozolomide
22
Specimen Handling
13
Radiotherapy
12
X-Rays
9
Biopsy
9
Radiation
8
trametinib
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Bevacizumab
6
larotrectinib
4
erdafitinib
4
dabrafenib
4
abemaciclib
4
ulixertinib
3
palbociclib
3
olaparib
3
Surgical Procedures, Operative
3
Nivolumab
3
D2C7-(scdsFv)-PE38KDEL
3
Cyclophosphamide
3
vorasidenib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
pembrolizumab
2
mirdametinib
2
lutetium Lu 177 dotatate
2
ivosidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
trastuzumab deruxtecan
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled